Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTx838 is a microbiome-modulating therapeutic candidate being developed by Primal Therapies for the treatment of bacterial vaginosis and yeast infections. The product consists of a combination of plant-based prebiotics and postbiotics designed to restore a healthy vaginal environment by selectively supporting the growth and dominance of beneficial *Lactobacillus* species. By promoting a *Lactobacillus*-dominant microbiome, PTx838 aims to displace pathogenic organisms and disrupt the biofilms associated with recurrent vaginal infections. It is currently in the feasibility stage of development, utilizing components that are generally recognized as safe (GRAS).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PTx838.